key: cord-0730401-4x0ckvwh authors: Nikolla, Dhimitri A.; Forehand, Brett R. title: Do Corticosteroids Reduce Mortality or Progression to Severe Disease for Non-Oxygen Requiring Patients Infected With COVID-19? date: 2022-04-21 journal: Ann Emerg Med DOI: 10.1016/j.annemergmed.2022.02.005 sha: 850adef42a6cfb83c718b5af5383a800b59942e7 doc_id: 730401 cord_uid: 4x0ckvwh nan The authors screened 2,990 studies and reviewed 145 full-text articles. After exclusions, they included 7 studies: 4 randomized controlled trials and 3 retrospective propensity score matching studies. These studies included 2,214 laboratoryconfirmed COVID-19 patients not requiring supplemental oxygen, 833 receiving systemic corticosteroid treatment, and 1,381 without. Although 6 of the 7 studies examined methylprednisolone, [6] [7] [8] [9] [10] [11] the study that contributed the most patients to the meta-analysis used a 6 mg/day dose of oral or intravenous dexamethasone for 10 days. 12 Systemic corticosteroid administration was associated with increased mortality and progression to severe disease (Table) . In Two independent investigators searched PubMed, Embase, Web of Science, and medRxiv databases from December 2019 to May 2021 using the terms COVID-19 (or synonyms) AND corticosteroids (or synonyms) OR dexamethasone OR methylprednisone OR hydrocortisone. The authors also examined the relevant article and related citation lists from PubMed. They did not restrict by country or publication language; however, they also did not report searching gray literature. The authors performed the search in accordance with the Preferred Reporting Items for Systematic Review and Metaanalyses (PRISMA) guidelines. 1 Two independent investigators selected randomized controlled trials and prospective or retrospective observational studies that used propensity score matching. They included studies evaluating the effectiveness of systemic corticosteroids in COVID-19 patients who did not require oxygen at the time of addition, systemic corticosteroid administration was associated with a longer duration of fever (standardized mean difference, 0.46; 95% confidence interval (CI), 0.15 to 0.76), a longer hospital length of stay (0.83; 95% CI, 0.61 to 1.05), and a shorter duration of viral clearance (0.20; 95% CI, 0.04 to 0.36). Not all patients with COVID-19 benefit from systemic corticosteroids. Systemic corticosteroids lower the 28-day all-cause mortality in critically ill COVID-19 patients who require supplemental oxygen. 13 However, a mortality benefit has not been observed in those who do not require supplemental oxygenation. 6, 7, 12 Furthermore, this review suggests that systemic corticosteroids are harmful in this nonhypoxemic cohort of COVID-19 patients, associated with higher mortality and progression to severe disease. 14 Although uncommon with COVID-19, 15 the authors suggest that corticosteroids may increase the risk of secondary bacterial infections. However, this study has several limitations. First, this review excluded inhaled corticosteroids, and the route of administration may be significant. Inhaled budesonide has been shown to reduce recovery time 16, 17 and the need for urgent medical care 16 among nonhospitalized COVID-19 patients. However, this recovery time benefit is not consistent among other inhaled corticosteroids, particularly ciclesonide. 18, 19 Additionally, despite a large number of patients, this meta-analysis includes a small number of studies, and all the studies had either a high or unclear risk of bias, which might compromise the validity of the results. Furthermore, the meta-analysis included propensity score matching observational studies, making the results susceptible to confounding. Next, the review does not address COVID-19 patients with concurrent asthma or chronic obstructive pulmonary disease exacerbations in whom systemic corticosteroids remain indicated despite normoxia. 20, 21 Also, only 3 studies explicitly excluded patients on chronic systemic corticosteroids. 6, 8, 9 Chronic systemic corticosteroid use is a risk factor for severe COVID-19 infection in, for example, asthma and chronic liver disease patients 22, 23 ; therefore, possible selection of these highrisk patients into the corticosteroid groups in the propensity score matching studies could have biased the results against corticosteroids. Lastly, the authors excluded studies from their analysis in which no patients died or progressed to severe disease in either treatment group. This exclusion may have introduced some selection bias where only studies with sicker patients were assessed, and sicker patients may have been more likely to get corticosteroids in the propensity score matching studies, making the corticosteroid group appear worse. In addition, the pooled mortality in this review was 13.7%, which is higher than the 1.2% to 7.0% overall COVID-19 mortality found in other studies. [24] [25] [26] [27] Therefore, illness severity may have confounded the results. Nevertheless, the a priori choice of mortality as an end point in these less critically ill patients with COVID-19 infections is less logical than in sicker cohorts. 13 World Health Organization. COVID-19 clinical management: living guidance The Cochrane Collaboration's tool for assessing risk of bias in randomised trials Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study Corticosteroids treatment of patients with coronavirus disease 2019: a propensity score matching study Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-Blind, randomized control trial Corticosteroid use in the treatment of COVID-19: a multicenter retrospective study in Hunan Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis Dexamethasone in hospitalized patients with COVID-19 Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and metaanalysis Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, openlabel, randomised controlled trial Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial Inhaled and intranasal ciclesonide for the treatment of COVID-19 in adult outpatients: CONTAIN phase II randomised controlled trial Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial COVID-19 rapid guideline: severe asthma. National Institute for Health and Care Excellence (NICE) Global Strategy for the Diagnosis. Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2022 Report. Global Initiative for Chronic Obstructive Lung Disease COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence Comparison of the impact of chronic corticosteroid therapy on critical care outcomes of COVID-19 patients with and without history of chronic liver disease Clinical characteristics and outcomes of non-icu hospitalization for COVID-19 in a nonepicenter, centrally monitored healthcare system Epidemiology, clinical characteristics, and outcomes of a large cohort of COVID-19 outpatients in Michigan COVID-19 hospitalizations in five California hospitals: a retrospective cohort study Outcomes of COVID-19 with the Mayo Clinic model of care and research Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis